Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Ongoing Initiated Dec 26, 2023 (3 years ago)

Benzonatate Capsules

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Superpotent drug: Assay results were slightly above specification at the time zero point.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Benzonatate Capsules, USP, 100 mg, 100 Capsules (10 capsules x 10 unit dose cards), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217. Carton NDC 68084-214-01; Individual Dose NDC 68084-214-11

Affected NDCs 68084-0214-01 68084-0214-11

Compare with the code on your package — it is the most precise check available.

Drug: Benzonatate

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Benzonatate
NDC 68084-0214
100 mg/1 Capsule
Oral
American Health Packaging Rx
Recalling firm
Amerisource Health Services LLC
NDC code
68084-214-01
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0257-2024 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm.

Other Benzonatate recalls

See all
Class I · High risk

Benzonatate capsules

Labeling: Label Mix-up: Bottle labeled as Benzonatate 100 mg capsules contained Benzphetamine 50 mg tablets and a bottle labeled as Benzphetamine 50 mg tablets contained Benzonatate 100 mg capsules.

Terminated Labeling / mix-up Calvin Scott & Company, Inc. NDC 67877-0573-05 D-1124-2022
Class III · Low risk

Benzonatate capsules

Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.

Terminated Stability / shelf life Strides Pharma INC NDC 64380-713-06 D-0858-2017
Class II · Moderate risk

Benzonatate Capsules

Failed Tablet/Capsule Specifications; recall initiated by manufacturer due to reports of wet capsules

Terminated Failed specification American Health Packaging NDC 68084-214-01 D-0430-2015
Class II · Moderate risk

Benzonatate Capsules

Failed Tablet/Capsule Specifications: Recall due to wet and/or leaking capsules.

Terminated Failed specification Zydus Pharmaceuticals USA Inc NDC 68382-247-01 D-0325-2015
Class II · Moderate risk

Benzonatate Capsules

Failed Tablet/Capsule Specifications: Recall due to wet and/or leaking capsules.

Terminated Failed specification Zydus Pharmaceuticals USA Inc NDC 68382-248-01 D-0299-2015

Other recalls by Amerisource Health Services LLC

All 2023 recalls
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Amerisource Health Services LLC D-0537-2026
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Amerisource Health Services LLC D-0536-2026
Class II · Moderate risk

Oxycodone Hydrochloride Tablets

Defective container: card seal defects (weak/non-existent seals), leading to the tablets falling out of their cavities.

Ongoing Packaging defect Amerisource Health Services LLC NDC 68084-354-01 D-0338-2026